The complete scope of Center Administration, a consortium Comprehensive Cancer Center with statewide responsibility and a cancer program deployed across the largest health system in the state, is broad-based and includes many and diverse functions; only the responsibilities and activities that support research throughout the matrix and across the consortium will be described and the funding request is further limited to those responsibilities and activities specifically allowable under CCSG guidelines. Administration was reviewed Outstanding in 2011, and over the last grant period continued to increase and evolve expert and stable support for: senior leadership; research programs; faculty affairs; workforce planning/performance; membership; developmental funds administration; strategic planning/evaluation; space planning/facilities; shared resources; clinical research infrastructure; community outreach; education/training. Administration continues to be led by Tanzer who serves as the Center?s senior administrative executive. Key Metrics Faculty Staff Total Operating Budget Full Members Associate Members * Direct Peer Reviewed Support ** Direct NCI Support Space Patient Visits 2011 2017 Net Increase 94 152 58 422 700 278 $75,603,349 $148,339,000 $72,735,651 159 165 6 2 62 60 $61,150,194 $71,061,938 $9,911,744 $18,664,885 $21,286,993 $2,622,108 270,000 sq. ft. 336,000 sq. ft. *** 66,000 sq. ft. *** 43,672 67,011 23,339 % Increase 62% 66% 96% 4% 3000% 16% 14% 24%* 53% * per the CCSG FOA, increase in associate members is due to the addition of investigators who contribute to the research objectives of the Center (e.g., development/implementation of clinical activity, authorship of clinical protocols, accrual of patients on interventional trials, etc.) and new investigators in their start-up period ** in order to provide an accurate comparison, all direct PR support in 2018 was compared to all direct PR support in 2011; 2018 data reported in Data Table 2 applies cancer relevance percentages and exclusion of center and training grants *** this will increase over the next grant period to 856,000 sq. ft. (net increase of 586,000, a 217% increase over 2011) with the construction of the new facility in New Brunswick and integration of Newark campus cancer center Since 2011, Administration implemented several enhancements to support the research mission of CINJ.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Rbhs -Cancer Institute of New Jersey
New Brunswick
United States
Zip Code
Zhu, Sining; Jin, Juan; Gokhale, Samantha et al. (2018) Genetic Alterations of TRAF Proteins in Human Cancers. Front Immunol 9:2111
Perekatt, Ansu O; Shah, Pooja P; Cheung, Shannon et al. (2018) SMAD4 Suppresses WNT-Driven Dedifferentiation and Oncogenesis in the Differentiated Gut Epithelium. Cancer Res 78:4878-4890
Llanos, Adana A M; Tsui, Jennifer; Rotter, David et al. (2018) Factors associated with high-risk human papillomavirus test utilization and infection: a population-based study of uninsured and underinsured women. BMC Womens Health 18:162
Hadigol, Mohammad; Khiabanian, Hossein (2018) MERIT reveals the impact of genomic context on sequencing error rate in ultra-deep applications. BMC Bioinformatics 19:219
Severson, Eric A; Riedlinger, Gregory M; Connelly, Caitlin F et al. (2018) Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens. Blood 131:2501-2505
Shih, Weichung Joe; Lin, Yong (2018) Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers. Stat Med 37:687-709
Ding, Qiang; Gaska, Jenna M; Douam, Florian et al. (2018) Species-specific disruption of STING-dependent antiviral cellular defenses by the Zika virus NS2B3 protease. Proc Natl Acad Sci U S A 115:E6310-E6318
Winer, Benjamin Y; Shirvani-Dastgerdi, Elham; Bram, Yaron et al. (2018) Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection. Sci Transl Med 10:
Modi, Parth K; Wang, Ye; Kirk, Peter S et al. (2018) The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications. Urology 117:50-56
Dai, Zhuqing; Feng, Simin; Liu, Anna et al. (2018) Anti-inflammatory effects of newly synthesized ?-galacto-oligosaccharides on dextran sulfate sodium-induced colitis in C57BL/6J mice. Food Res Int 109:350-357

Showing the most recent 10 out of 775 publications